Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvage Chemotherapy and Allogeneic HSCT for High-Risk/Relapsed Hodgkin Lymphoma
NCT00574496Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2007
- Primary completion
- Aug 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifosfamide, gemcitabine, vinorelbine, mechlorethamine, vincristine in Hodgkin lymphoma (HL), sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2007; status: completed.
02
Drugs
ifosfamidegemcitabinevinorelbinemechlorethaminevincristine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00574496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00574496.